Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    In: Faraday Discuss., Royal Society of Chemistry (RSC), Vol. 171 ( 2014), p. 57-80
    Type of Medium: Online Resource
    ISSN: 1359-6640 , 1364-5498
    Language: English
    Publisher: Royal Society of Chemistry (RSC)
    Publication Date: 2014
    detail.hit.zdb_id: 1472891-6
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 2
    Online Resource
    Online Resource
    American Association for Cancer Research (AACR) ; 2018
    In:  Cancer Research Vol. 78, No. 13_Supplement ( 2018-07-01), p. 4040-4040
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 78, No. 13_Supplement ( 2018-07-01), p. 4040-4040
    Abstract: Pancreatic ductal adenocarcinoma (PDAC) is a highly malignant tumor characterized by intrinsic or rapidly acquired chemoresistance. The remarkable desmoplastic response has been reported as a major contributor to chemoresistance, suggesting that PDAC progression could be highly influenced by mechanical factors (1). A recent study showed a key role of epithelial tension and matricellular fibrosis in the aggressiveness of SMAD4 mutant PDAC (2). Here we aimed at evaluating new mechanopharmacology approaches to overcome chemoresistance. PDAC cells attached to collagen and fibronectin showed a decreased sensitivity to chemotherapy, while the malignant phenotype was highly correlated to α2β1 integrin(ITGA2)-mediated adhesion to type I collagen (3). We hence hypothesized that this integrin might modulate chemoresistance. In two cohorts of 50 radically resected patients treated with gemcitabine, high expression of ITGA2 (assessed by immunohistochemistry in tissue-microarrays with 4 cores for each tumor) correlated to significantly shorter progression and overall free survival. Our hypothesis was further investigated in a gemcitabine-resistant clone (PANC1-R). In this clone, ITGA2 was among the top 10 most differentially upregulated genes at next-generation sequencing analysis. Using migration assays, we found that PANC1-R were more invasive than PANC1 cells, and a specific siRNA for ITGA2 caused a significant reduction of invasiveness while enhancing both gemcitabine antiproliferative effects and apoptosis induction. Using elastic micropillar arrays of varying stiffness (20-150kPa) (4), we observed delayed spreading of PANC1-R compared to PANC1 while a 24-hour treatment with a non-cytotoxic dose of gemcitabine activated traction forces in both lines, albeit to a lesser extent in PANC1-R. Remarkably, these cells showed also a significant increase of CXCR4 and MMP2 expression when growing in spheroids embedded in stiff collagen, as well as a different trend in modulation of E2F1 after exposure to gemcitabine, when growing as 2D collagen monolayers on soft and stiff flat PDMS, suggesting that aggressive/invasive behavior and response to gemcitabine are altered by both collagen and stiffness. These results define ITGA2 as a new prognostic factor, exerting its function through the promotion of metastatic behavior and altered drug response of PDAC cells under differential biomechanical conditions, which holds a potential as a novel therapeutic target to overcome PDAC resistance. References: 1. Coppola et al. Drug Resist Updates 2017;31:43. 2. Laklai et al. Nat Med 2016;22:497. 3. Grzesiak, Bouvet. Br J Cancer 2016;94:1311. 4. van Hoorn et al. Nano Lett 2014;14:4257. Citation Format: Ilaria Carnevale, Stefano Coppola, Niccola Funel, Erik H. Danen, Thomas Schmidt, Elisa Giovannetti. α2β1 integrins are potential regulators of chemoresistance through modulation of biomechanical cues in pancreatic cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 4040.
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2018
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 3
    In: Cancers, MDPI AG, Vol. 11, No. 5 ( 2019-05-08), p. 638-
    Abstract: Pancreatic stellate cells (PSCs) are a key component of tumor microenvironment in pancreatic ductal adenocarcinoma (PDAC) and contribute to drug resistance. c-MET receptor tyrosine kinase activation plays an important role in tumorigenesis in different cancers including PDAC. In this study, effects of PSC conditioned medium (PCM) on c-MET phosphorylation (by immunocytochemistry enzyme-linked immunosorbent assay (ELISA)) and drug response (by sulforhodamine B assay) were investigated in five primary PDAC cells. In novel 3D-spheroid co-cultures of cyan fluorescence protein (CFP)-firefly luciferase (Fluc)-expressing primary human PDAC cells and green fluorescence protein (GFP)-expressing immortalized PSCs, PDAC cell growth and chemosensitivity were examined by luciferase assay, while spheroids’ architecture was evaluated by confocal microscopy. The highest phospho-c-MET expression was detected in PDAC5 and its subclone sorted for “stage specific embryonic antigen-4” (PDAC5 (SSEA4)). PCM of cells pre-incubated with PDAC conditioned medium, containing increased hepatocyte growth factor (HGF) levels, made PDAC cells significantly more resistant to gemcitabine, but not to c-MET inhibitors. Hetero-spheroids containing both PSCs and PDAC5 (SSEA4) cells were more resistant to gemcitabine compared to PDAC5 (SSEA4) homo-spheroids. However, c-MET inhibitors (tivantinib, PHA-665752 and crizotinib) were equally effective in both spheroid models. Experiments with primary human PSCs confirmed the main findings. In conclusion, we developed spheroid models to evaluate PSC–PDAC reciprocal interaction, unraveling c-MET inhibition as an important therapeutic option against drug resistant PDAC.
    Type of Medium: Online Resource
    ISSN: 2072-6694
    Language: English
    Publisher: MDPI AG
    Publication Date: 2019
    detail.hit.zdb_id: 2527080-1
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. Further information can be found on the KOBV privacy pages